These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 25172236

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Renal tubular function in children with tyrosinaemia type I treated with nitisinone.
    Santra S, Preece MA, Hulton SA, McKiernan PJ.
    J Inherit Metab Dis; 2008 Jun; 31(3):399-402. PubMed ID: 18509744
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. HCC prevalence and histopathological findings in liver explants of patients with hereditary tyrosinemia type 1.
    Seda Neto J, Leite KM, Porta A, Fonseca EA, Feier FH, Pugliese R, Miura IK, Chapchap P, Porta G.
    Pediatr Blood Cancer; 2014 Sep; 61(9):1584-9. PubMed ID: 24852359
    [Abstract] [Full Text] [Related]

  • 7. Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec.
    Larochelle J, Alvarez F, Bussières JF, Chevalier I, Dallaire L, Dubois J, Faucher F, Fenyves D, Goodyer P, Grenier A, Holme E, Laframboise R, Lambert M, Lindstedt S, Maranda B, Melançon S, Merouani A, Mitchell J, Parizeault G, Pelletier L, Phan V, Rinaldo P, Scott CR, Scriver C, Mitchell GA.
    Mol Genet Metab; 2012 Sep; 107(1-2):49-54. PubMed ID: 22885033
    [Abstract] [Full Text] [Related]

  • 8. Experience with NTBC therapy in hereditary tyrosinaemia type I: an alternative to liver transplantation.
    Joshi SN, Venugopalan P.
    Ann Trop Paediatr; 2004 Sep; 24(3):259-65. PubMed ID: 15479577
    [Abstract] [Full Text] [Related]

  • 9. Evolution of tyrosinemia type 1 disease in patients treated with nitisinone in Spain.
    Couce ML, Sánchez-Pintos P, Aldámiz-Echevarría L, Vitoria I, Navas V, Martín-Hernández E, García-Volpe C, Pintos G, Peña-Quintana L, Hernández T, Gil D, Sánchez-Valverde F, Bueno M, Roca I, López-Ruzafa E, Díaz-Fernández C.
    Medicine (Baltimore); 2019 Sep; 98(39):e17303. PubMed ID: 31574857
    [Abstract] [Full Text] [Related]

  • 10. Hereditary tyrosinemia type 1 in Turkey: twenty year single-center experience.
    Zeybek AC, Kiykim E, Soyucen E, Cansever S, Altay S, Zubarioglu T, Erkan T, Aydin A.
    Pediatr Int; 2015 Apr; 57(2):281-9. PubMed ID: 25223216
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Tyrosinemia type I: Case series with response to treatment to NTBC.
    Shah I, Shah F.
    Indian J Gastroenterol; 2016 May; 35(3):229-31. PubMed ID: 27109516
    [Abstract] [Full Text] [Related]

  • 13. LC-MS/MS method for simultaneous determination on a dried blood spot of multiple analytes relevant for treatment monitoring in patients with tyrosinemia type I.
    la Marca G, Malvagia S, Materazzi S, Della Bona ML, Boenzi S, Martinelli D, Dionisi-Vici C.
    Anal Chem; 2012 Jan 17; 84(2):1184-8. PubMed ID: 22148291
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Extensive changes in liver gene expression induced by hereditary tyrosinemia type I are not normalized by treatment with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC).
    Luijerink MC, Jacobs SM, van Beurden EA, Koornneef LP, Klomp LW, Berger R, van den Berg IE.
    J Hepatol; 2003 Dec 17; 39(6):901-9. PubMed ID: 14642604
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.